5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | BUY | BUY | BUY | NEUTRAL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 2.81▼ | 2.80▼ | 2.80▼ | 2.76▲ | 2.69▲ |
MA10 | 2.81▼ | 2.79▼ | 2.79▼ | 2.71▲ | 2.36▲ |
MA20 | 2.81▼ | 2.78▲ | 2.77▲ | 2.63▲ | 3.16▼ |
MA50 | 2.79▼ | 2.76▲ | 2.74▲ | 2.29▲ | 4.23▼ |
MA100 | 2.78▲ | 2.73▲ | 2.68▲ | 3.44▼ | N/A |
MA200 | 2.76▲ | 2.67▲ | 2.45▲ | 4.23▼ | N/A |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.002▼ | 0.000▲ | 0.001▲ | 0.018▲ | 0.096▲ |
RSI | 44.306▼ | 53.119▲ | 56.169▲ | 62.649▲ | 41.669▼ |
STOCH | 36.111 | 56.574 | 46.077 | 87.321▲ | 52.796 |
WILL %R | -100.000▼ | -63.158 | -48.000 | -11.712▲ | -55.107 |
CCI | -58.065 | 51.852 | 83.243 | 111.408▲ | 35.007 |
Tuesday, March 18, 2025 01:46 AM
We recently published a list of 10 Best Short-Term Stocks To Buy Right Now. In this article, we are going to take a look at where Acelyrin, Inc. (NASDAQ:SLRN) stands against other best short-term ...
|
Thursday, March 13, 2025 05:00 PM
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative ...
|
Thursday, March 13, 2025 05:00 PM
LOS ANGELES, March 13, 2025 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of transformative ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
19/03/25 | 2.82 | 2.855 | 2.75 | 2.79 | 850,769 |
18/03/25 | 2.75 | 2.82 | 2.71 | 2.82 | 890,712 |
17/03/25 | 2.75 | 2.76 | 2.71 | 2.75 | 406,643 |
14/03/25 | 2.73 | 2.76 | 2.70 | 2.75 | 565,017 |
13/03/25 | 2.77 | 2.795 | 2.67 | 2.69 | 970,812 |
12/03/25 | 2.67 | 2.7999 | 2.6357 | 2.75 | 1,441,939 |
11/03/25 | 2.63 | 2.705 | 2.59 | 2.67 | 1,146,500 |
10/03/25 | 2.60 | 2.62 | 2.54 | 2.605 | 788,465 |
07/03/25 | 2.65 | 2.77 | 2.64 | 2.65 | 1,436,051 |
06/03/25 | 2.52 | 2.68 | 2.465 | 2.66 | 1,640,458 |
|
|
||||
|
|
||||
|
|